~~<i id='1FBB3F2CB2'><strike id='1FBB3F2CB2'><tt id='1FBB3F2CB2'><pre id='1FBB3F2CB2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：explore 2025-09-30 17:29:00 - browse：869

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

focus

knowledge

leisure time

Wikipedia

hotspot

DarronCummings/APThebenefitsandrisksofEliLilly’streatmentforAlzheimer’sdiseasewereconfirmedindetaile

WSS

US intelligence assessment says Iran not currently developing nuclear weapons

A public scorecard can help hold safety

Listen: Wegovy in the brain & pivotal Alzheimer's data

How Medicaid coverage policies for immigrants impact new moms

At Orexo, a ‘turning point’ for everything but digital health

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

focus

entertainment

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

How one medical school became remarkably diverse

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

DIEP, the 'gold standard' of breast reconstruction, is under threat

The PBM ad wars are taking over Washington, D.C.

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Listen: Wegovy in the brain & pivotal Alzheimer's data

Walensky prepares to leave CDC — and Congress — behind

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

knowledge

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

FDA approves Leqembi, a milestone in Alzheimer’s treatment

How redistricting in 6 states could affect who controls Congress

A public scorecard can help hold safety

What to know about a major upcoming Wegovy heart health study

WHO calls for emergency meeting on new China virus, as cases spread

knowledge

leisure time

Wikipedia

hotspot